ArticleCancer science2011

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.

Masashi Takawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.